– Breadth of Alto’s pipeline and Precision Psychiatry Platform™ will be highlighted across twelve posters and presentations at the Society of Biological Psychiatry and American Society of Clinical ...

Results support advancement of 10 mg dose into Phase 3 development –– End-of-Phase 2 meeting request accepted by U.S. FDA; partnership ...

Presentation will cover two-year clinical efficacy, immunogenicity and safety dataData will be presented at an oral session on October 17, 2025, followed by a webinar on October 22, 2025, providing ...

NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials and the ...

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced updated data presentations including new six-year data from the ULTIMATE I & II Phase 3 trials ...

Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, announced today that two abstracts have been accepted for poster ...

Quanta Therapeutics, a privately-held clinical-stage biopharmaceutical company leading the development of innovative, oral therapeutics for RAS-driven cancers, today announced it will present Phase 1 ...

NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials ...

CHICAGO--(BUSINESS WIRE)--Researchers from Veradigm ®, a leading provider of healthcare data and technology solutions, will present health economics and outcomes research (HEOR) data on Covid-19, ...

Many Data Summit speakers have made their presentations available online for attendees to view. Presentations will remain on the website during and after the conference so that you can refer to them ...

Initial Safety and Efficacy Data for NKTR-255, a Novel IL-15 Agonist, in Combination with Cetuximab in Solid Tumors Presented in Late-Breaking Abstract Session SAN FRANCISCO, Nov. 12, 2021 /PRNewswire ...

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI ® (ublituximab-xiiy) data in patients ...